Evidence map›Paper›PMID 21719790›Full record

ArticleJournal of the American Society of Nephrology : JASN2011

The inflammatory cytokines TWEAK and TNFα reduce renal klotho expression through NFκB.

Juan A Moreno, Maria C Izquierdo, Maria D Sanchez-Niño, Beatriz Suárez-Alvarez, Carlos Lopez-Larrea, Aniela Jakubowski, Julia Blanco, Rafael Ramirez, Rafael Selgas, Marta Ruiz-Ortega and 3 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04936282 (Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients), which is not on this map. Cited by 207 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
207citing papers in PubMed, 1 pooled it
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04936282 phase4unknown statusnot on this mapstarted 2022, after this paper: background citation

Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients: a Spanish Multicenter, Randomized, Controlled Parallel-group Trial: The TRAINING Study

TypeinterventionalSponsorFundación Canaria Instituto de Investigación Sanitaria de CanariasRan2022 to 2024Enrolled80ConditionsKidney Transplant Failure and RejectionArmsGrafalon, Normal Treatment
3 · Its place in the literature

Who cites it

207 citing papers in PubMed, 1 synthesis or guideline pooled it, 384 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Anti-aging effects of glycyrrhizin via maintaining Klotho levels.Journal of clinical biochemistry and nutrition · 2026
    Article
  5. Review
  6. Review
  7. Serum α-Klotho and SIRT1 - Relationship with graft function, inflammation and hospitalization rates in kidney transplant recipients.Transplant international : official journal of the European Society for Organ Transplantation · 2026
    Observational
  8. Article
  9. [Potential of early diagnosis and targeted therapy for Klotho protein in chronic kidney disease].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025
    Review
  10. Review
  11. Article
  12. Review
  13. The role of the intestinal microbiome in cognitive decline in patients with kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

147 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 2 countries.

Juan A MorenoIIS-Fundación Jiménez Díaz, Universidad Autónoma de Madrid and Fundación Renal Iñigo Alvarez de Toledo, Madrid, Spain.
Maria C Izquierdo
Maria D Sanchez-Niño
Beatriz Suárez-Alvarez
Carlos Lopez-Larrea
Aniela Jakubowski
Julia Blanco
Rafael Ramirez
Rafael Selgas
Marta Ruiz-Ortega
Jesus Egido
Alberto Ortiz
Ana B Sanz
Fundación Renal Española · ESUniversidad Autónoma de Madrid · ESHospital Universitario Central de Asturias · ESBiogen (United States) · USHospital Clínico San Carlos · ESHospital La Paz Institute for Health Research · ESHospital Universitario Reina Sofía · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proinflammatory cytokines contribute to renal injury, but the downstream effectors within kidney cells are not well understood. One candidate effector is Klotho, a protein expressed by renal cells that has antiaging properties; Klotho-deficient mice have an accelerated aging-like phenotype, including vascular injury and renal injury. Whether proinflammatory cytokines, such as TNF and TNF-like weak inducer of apoptosis (TWEAK), modulate Klotho is unknown. In mice, exogenous administration of TWEAK decreased expression of Klotho in the kidney. In the setting of acute kidney injury induced by folic acid, the blockade or absence of TWEAK abrogated the injury-related decrease in renal and plasma Klotho levels. TWEAK, TNFα, and siRNA-mediated knockdown of IκBα all activated NFκB and reduced Klotho expression in the MCT tubular cell line. Furthermore, inhibition of NFκB with parthenolide prevented TWEAK- or TNFα-induced downregulation of Klotho. Inhibition of histone deacetylase reversed TWEAK-induced downregulation of Klotho, and chromatin immunoprecipitation showed that TWEAK promotes RelA binding to the Klotho promoter, inducing its deacetylation. In conclusion, inflammatory cytokines, such as TWEAK and TNFα, downregulate Klotho expression through an NFκB-dependent mechanism. These results may partially explain the relationship between inflammation and diseases characterized by accelerated aging of organs, including CKD.

Indexed as

Acute Kidney InjuryAnimalsCells, CulturedCytokine TWEAKDown-RegulationGlucuronidaseHistone DeacetylasesKlotho ProteinsMiceMice, Inbred C57BLNF-kappa BRNA, MessengerTumor Necrosis Factor-alphaTumor Necrosis FactorsCytokine TWEAKGlucuronidaseHistone DeacetylasesKlotho ProteinsNF-kappa BRNA, MessengerTnfsf12 protein, mouseTumor Necrosis Factor-alphaTumor Necrosis Factors

Identifiers

PMID21719790
PMCPMC3137579
OpenAlexW2102244214

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.